Aslan Pharmaceuticals shares slide amid new data on atopic dermatitis treatment
ASLNDelisted Stock | USD 0.60 0.03 4.76% |
About 62% of Aslan Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Aslan Pharmaceuticals suggests that many traders are alarmed regarding Aslan Pharmaceuticals' prospects. Aslan Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Aslan Pharmaceuticals. Many technical investors use Aslan Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Aslan |
Shares of Aslan Pharmaceuticals were down 32 percent premarket on Thursday after the company released new data from a clinical study of eblasakimab, an atopic...
Read at marketwatch.com
Aslan Pharmaceuticals Fundamental Analysis
We analyze Aslan Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Aslan Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Aslan Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aslan Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aslan Pharmaceuticals Related Equities
CTMX | CytomX Therapeutics | 12.84 | ||||
LYRA | Lyra Therapeutics | 10.53 | ||||
ANEB | Anebulo Pharmaceuticals | 7.64 | ||||
ADAG | Adagene | 6.39 | ||||
NAMS | NewAmsterdam Pharma | 1.73 | ||||
ACRV | Acrivon Therapeutics, | 0.13 | ||||
AGIO | Agios Pharm | 0.02 | ||||
IVA | Inventiva | 0.38 | ||||
ACHL | Achilles Therapeutics | 0.93 | ||||
AVTE | Aerovate Therapeutics | 1.50 | ||||
GPCR | Structure Therapeutics | 2.03 | ||||
ASMB | Assembly Biosciences | 2.09 | ||||
CMPX | Compass Therapeutics | 2.41 | ||||
CGEM | Cullinan Oncology | 2.81 | ||||
TIL | Instil Bio | 2.86 | ||||
GLUE | Monte Rosa | 3.52 | ||||
IOBT | IO Biotech | 4.44 | ||||
MLYS | Mineralys Therapeutics, | 4.60 | ||||
ERAS | Erasca | 4.95 | ||||
ANTX | AN2 Therapeutics | 6.25 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Aslan Stock
If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |